Impact of molecular profiling on clinical trial design for glioblastoma

Current Oncology Reports

Volumn 9, Issue 1, 2007, Pages 71-79

  Chakravarti, Arnab ^a   Tyndall, Erin ^b   Palanichamy, Kamalakannan ^b   Mehta, Minesh ^b   Aldape, Kenneth ^b   Loeffler, Jay ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; CORTICOSTEROID; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NOTCH RECEPTOR; OSTEONECTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; PROTEIN KINASE B; SEMAPHORIN; SURVIVIN; TEMOZOLOMIDE; TEMSIROLIMUS; VATALANIB;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN EDEMA; CLINICAL RESEARCH; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG WITHDRAWAL; EXCISION REPAIR; EXPERIMENTAL DESIGN; FATIGUE; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MISMATCH REPAIR; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PROGNOSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; RESEARCH DESIGN; SIGNAL TRANSDUCTION;

EID: 33846130612     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02951429     Document Type: Review

References (45)

1. Newlands ES, Stevens MF, Wedge SR, et al.: Temozolomide: a review of its discovery, chemical properties, pre-clinical development, and clinical trials. Cancer Treat Rev 1997, 23:35-61.
2. Wedge SR, Porteous JK, Glaser MG, et al.: In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997, 8:92-97.
3. Newlands ES, Blackledge G, Slack RS: Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856). Br J Cancer 1992, 65:287-291.
4. Yung WK, Albright RE, Olson J, et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma at first relapse. Br J Cancer 2000, 83:588-593.
5. Stupp R, Dietrich PY, Ostermann Kralievic S, et al.: Promising survival for patients with newly-diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375-1382
6. Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
7. Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005, 352:997-1003.
8. Hackel PO, Zwick E, Prenzel N, Ullrich A. et al.: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11:184-189.
9. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999: 82:241-250.
10. Zwick E, Prenzel N, Ullrich A. et al.: The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 1999, 20:408-412.
11. Maher EA, Furnari FB, Bachoo RM, et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001. 15:1311-1333.
12. Ang K K, Berkey BA, Tu X, et al.: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
13. Baselga J, Albanell J: Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 2002, 4:317-324.
14. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7(Suppl 4):2-8.
15. Balaban N, Moni J, Shannon M, et al.: The effect of ionizing radiation on signal transduction: antibodies to EGF recept sensitize A431 cells to radiation. Biochim Biopbys Acta 1996,1314:147-156.
16. Chakravarti A, Dicker A, Mehta M: The contribution of EGFR signaling in human gliomas: a review of preclinical and correlative data. Int J Radiat Oncol Biol Phys 2004, 58:927-931.
17. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through the continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
18. Chakravarti A, Chakladar A, Delaney MA, et al.: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner. Cancer Res 2002, 62:4307-4315.
19. Ciardiello F, Bianco R, Damiano V, et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000, 6:3739-3747.
20. Ciardiello F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000, 60(Suppl 1):25-32; discussion 41-42.
21. Dent P, Reardon DB, Park JS, et al.: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999, 10:2493-2506.
22. Barker FG II, Simmons ML, Chang SM, et al.: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51:410-418.
23. Shinojima N, Tada K, Shiraishi S, et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63:6962-6970.
24. Chakravarti A, Delaney MA, Noll E, et al.: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001, 7.2387-2395.
25. Etienne M-C, Formento JL, Lebrun-Frenay C, et al.: Epidermal growth factor receptor and labeling index are independent prognostic factors in glial turmor outcome. Clin Cancer Res 1998, 4:2383-2390.
26. Feldkamp MM, Lala P, Lau N, et al.: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999,4S:1442-1453.
27. Smith JS, Tachibana I, Passe SM, et al.: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93:1246-1256.
28. Rainov NG, Dobberstein KU, Bahn H: Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 1997, 35:13-28.
29. Chakravarti A, Seiferheld W, Tu X, et al.: Immumohistochemically determined total EGFR levels are not of prognostic value in newly diagnosed GBM: A Report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005, 62:318-327.
30. Buckner JC, Aldape KD, Ballman K, et al.: Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. J Clin Oncol 2004, 22(14S):1505.
31. Prados M, Yung W, Wen P, et al.: Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. J Clin Oncol 2004, 22(14s):lSO4.
32. Rich J, Reardon DA, Peery T, et al.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
33. Prados M, Chang S, Burton E, et al.: Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma [abstract]. Proc ASCO 2003, 22:99.
34. Chakravarti A, Zhai G, Suzuki Y, et al.: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004, 22:1926-1933.
35. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of physphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
36. Chakravarti A, Seiferfeld W, Robins H, et al.: An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+radiation for newly-diagnosed GBM patients. J Clin Oncol 2004, 22(14S):1571.
37. Galanis E, Buckner JC, Maurer M, al.: NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). J Clin Oncol 2004, 22(14S):1503.
38. Conrad C, Friedman H, Reardon D, et al.: A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent GBM. J Clin Oncol 2004, 22(14S):1512.
39. Reardon DA, Friedman HS, Yung WKA, et al.: A phase I/II trial of PTK-787/ ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent GBM. J Clin Oncol 2004, 22(14S):1513.
40. Rich JN, Hans C, Jones B, et al.: Gene expression profiling and genetic markers in glioblastoma, survival. Cancer Res 2005, 65:4051-4058.
41. Liang Y, Diehn M, Watson N, et al.: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005, 102:5814-5819.
42. Freije WA, Castro-Vargas FE, Fang Z: Gene expression profiles of gliomas strongly predicts survival. Cancer Res 2004, 64:6503-6510.
43. Chakravarti A, Noll E, Black PM, et al.: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002, 20:1063-1068.
44. Chakravarti A, Zhai GG, Zhang M, et al.: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004, 23:7494-7506.
45. Phillips H, Kharbanda S, Chen R, et al.: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.